SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior

Molecular Genetics and Metabolism

Volumn 88, Issue 4, 2006, Pages 384-388

  Shaldubina, Alona ^a   Johanson, Roy A ^b   O'Brien, W Timothy ^c   Buccafusca, Roberto ^b   Agam, Galila ^a   Belmaker, R H ^a   Klein, Peter S ^c   Bersudsky, Yuly ^a   Berry, Gerard T ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Behavior; Bipolar disorder; GSK 3; Inositol; Inositol monophosphatase (IMPase); Lithium; SMIT1

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; INOSITOL; LITHIUM; PHOSPHATIDYLINOSITOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE; GENE FUNCTION; GENOTYPE; HAPLOIDY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SODIUM MYOINOSITOL COTRANSPORTER1 GENE;

ANIMALS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; BRAIN; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; INOSITOL; LITHIUM; MICE; SYMPORTERS;

EID: 33746269699     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.03.007     Document Type: Article

References (27)

1. Hallcher L.M., and Sherman W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255 (1980) 10896-10901
2. York J.D., Guo S., Odom A.R., Spiegelberg B.D., and Stolz L.E. An expanded view of inositol signaling. Adv. Enzyme Regul. 41 (2001) 57-71
3. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93 (1996) 8455-8459
4. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96 (2002) 45-66
5. Berridge M.J., Downes C.P., and Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 59 (1989) 411-419
6. Allison J.H., and Stewart M.A. Reduced brain inositol in lithium-treated rats. Nat. New Biol. 233 43 (1971) 267-268
7. O'Donnell T., Rotzinger S., Nakashima T.T., Hanstock C.C., Ulrich M., and Silverstone P.H. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res. 880 (2000) 84-91
8. Williams R.S., Cheng L., Mudge A.W., and Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 417 (2002) 292-295
9. Kofman O., and Belmaker R.H. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol. Psychiatr. 24 (1993) 839-852
10. Baraban J.M. Toward a crystal-clear view of lithium's site of action. Proc. Natl. Acad. Sci. USA 91 (1994) 5738-5739
11. Jope R.S., and Williams M.B. Lithium and brain signal transduction systems. Biochem. Pharmacol. 47 (1994) 429-441
12. Berry G.T., Wu S., Buccafusca R., Ren J., Gonzales L.W., Ballard P.L., Golden J.A., Stevens M.J., and Greer J.J. Loss of murine Na+/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea. J. Biol. Chem. 278 (2003) 18297-18302
13. Berry G.T., Buccafusca R., Greer J.J., and Eccleston E. Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain. Mol. Genet. Metab. 82 (2004) 87-92
14. Bersudsky Y., Kaplan Z., Shapiro Y., Agam G., Kofman O., and Belmaker R.H. Behavioral evidence for the existence of two pools of cellular inositol. Eur. Neuropsychopharmacol. 4 (1994) 463-467
15. Stambolic V., Ruel L., and Woodgett J. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr. Biol. 6 (1996) 664-1668
16. Munoz-Montano J.R., Moreno F.J., Avila J., and Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411 (1997) 183-188
17. Porsolt R.D., Bertin A., and Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
18. O'Brien W.T., Harper A.D., Jove F., Woodgett J.R., Maretto S., Piccolo S., and Klein P.S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004) 6791-6798
19. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., and Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. USA 101 (2004) 5099-5104
20. Gould T.D., Einat H., Bhat R., and Manji H.K. AR-A014418, a selective Gsk-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7 (2004) 387-390
21. Kaidanovich-Beilin O., and Eldar-Finkelman H. Long term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob Mice: Molecular characterization in liver and muscle. Pharmacol. Exp. Ther. 316 (2006) 17-24
22. Shears S.B. How versatile are inositol phosphate kinases?. Biochem. J. 377 (2004) 265-280
23. Nonaka S., Katsube N., and Chuang D.M. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J. Pharmacol. Exp. Ther. 286 (1998) 539-547
24. Sconzo G., Cascino D., Amore G., Geraci F., and Giudice G. Effect of the IMPase inhibitor L690,330 on sea urchin development. Cell Biol. Int. 22 (1998) 91-94
25. Wang X., Liu X.T., Dunn R., Ohl D.A., and Smith G.D. Glycogen synthase kinase-3 regulates mouse oocyte homologue segregation. Mol. Reprod. Dev. 64 (2003) 96-105
26. Agam G., Shapiro Y., Bersudsky Y., Kofman O., and Belmaker R.H. High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithium. Pharmacol. Biochem. Behav. 49 (1994) 341-343
27. Hedgepeth C.M., Conrad L.J., Zhang J., Huang H.-C., Lee V.M., and Klein P.S. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev. Biol. 185 (1997) 82-91